BamSEC and AlphaSense Join Forces
Learn More

Sionna Therapeutics Inc. – Material Contracts

NASDAQ: SION    
Share price (5/22/26): $41.13    
Market cap (5/22/26): $1.857 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.7
from 10-K 3 pages Sionna Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.8
from S-1/A 7 pages Sionna Therapeutics, Inc. Compensation Recovery Policy Adopted as of December 12, 2024, Subject to Effectiveness of the Company’s Registration Statement on Form S-1 for Its Initial Public Offering
12/34/56
EX-10.7
from S-1/A 3 pages Sionna Therapeutics, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.6
from S-1/A 15 pages Sionna Therapeutics, Inc. Severance and Change in Control Plan
12/34/56
EX-10.5
from S-1/A 3 pages Sionna Therapeutics, Inc. Senior Executive Cash Incentive Bonus Plan
12/34/56
EX-10.4
from S-1/A 34 pages Sionna Therapeutics, Inc. Indemnification Agreement
12/34/56
EX-10.3
from S-1/A 11 pages Sionna Therapeutics, Inc. 2025 Employee Stock Purchase Plan
12/34/56
EX-10.2
from S-1/A 54 pages Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan
12/34/56
EX-10.15
from S-1 86 pages Genesis 21 Hickory Lease Bp3-Bos6 21 Hickory LLC, a Delaware Limited Liability Company, as Landlord, and Sionna Therapeutics, Inc., a Delaware Corporation, as Tenant Summary of Basic Lease Information
12/34/56
EX-10.14
from S-1 5 pages August 20, 2021 Elena Ridloff [Omitted] Re: Employment Offer Dear Elena: On Behalf of Sling Therapeutics, Inc., a Delaware Corporation (The “Company”), I Am Pleased to Offer You the Position of the Company’s Chief Financial Officer and (“CFO”). if Accepted, This Letter Agreement Sets Forth the Terms and Conditions of Your Employment (The “Agreement”)
12/34/56
EX-10.13
from S-1 7 pages May 7, 2021 Charlotte M. McKee, M.D. [Omitted] Re: Employment Offer Dear Charlotte
12/34/56
EX-10.12
from S-1 5 pages March 8, 2021 Michael J. Cloonan [Omitted] Re: Employment Offer Dear Michael: On Behalf of Sling Therapeutics, Inc., a Delaware Corporation (The “Company”), I Am Pleased to Offer You the Position of the Company’s President and Chief Executive Officer and (“CEO”). if Accepted, This Letter Agreement Sets Forth the Terms and Conditions of Your Employment (The “Agreement”)
12/34/56
EX-10.11
from S-1 34 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. Payment Agreement Between Cystic Fibrosis Foundation and Sling Therapeutics, Inc. Dated as of December 20, 2019
12/34/56
EX-10.10
from S-1 71 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. License Agreement Between Abbvie Global Enterprises Ltd. and Sionna Therapeutics, Inc. Effective July 11, 2024 Confidential
12/34/56
EX-10.9
from S-1 61 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. License Agreement Between Sanofi and Sling Therapeutics, Inc. Dated as of December 20, 2019
12/34/56
EX-10.8
from S-1 7 pages Sionna Therapeutics, Inc. Compensation Recovery Policy Adopted as of [ ], 2024, Subject to Effectiveness of the Company’s Registration Statement on Form S-1 for Its Initial Public Offering
12/34/56
EX-10.6
from S-1 15 pages Sionna Therapeutics, Inc. Severance and Change in Control Plan Effective Date: [Month] [Date], 2024
12/34/56
EX-10.5
from S-1 3 pages Sionna Therapeutics, Inc. Senior Executive Cash Incentive Bonus Plan
12/34/56
EX-10.1
from S-1 54 pages Sionna Therapeutics, Inc. 2020 Stock Option and Grant Plan
12/34/56
EX-10.8
from DRS/A 61 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It Is (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed. License Agreement Between Sanofi and Sling Therapeutics, Inc. Dated as of December 20, 2019
12/34/56